Wikipedia

GeneDx

GeneDx is an American biotechnology company specializing in genomic diagnostics, with a focus on whole genome sequencing (WGS) and whole exome sequencing (WES) for the diagnosis of rare and inherited disorders.[1] The company provides genetic testing services to healthcare providers, hospitals, and health systems, and contributes to advancements in genomic medicine through research, biopharma partnerships, and advocacy. The company is headquartered in Stamford, Connecticut, with its clinical laboratory in Gaithersburg, Maryland, and is publicly traded on the Nasdaq under the ticker symbol WGS.[2]

GeneDx
Company type
Public
Nasdaq: WGS
IndustryBiotechnology, genome testing
Founded2000; 26 years ago (2000)
FounderSherri Bale, John Compton
Headquarters
Stamford, CT
Key people
  • Katherine Stueland (CEO)
  • Kevin Feeley (CFO)
  • Bryan Dechairo (COO)
  • Jason Ryan (Executive Chair of the Board)
ProductsExome/genome sequencing
Websitewww.genedx.com

GeneDx was founded in 2000 by Sherri Bale and John Compton, scientists from the National Institutes of Health (NIH), to provide diagnostic services for patients with rare and ultra-rare disorders.[3][4][5] The company was acquired by BioReference Laboratories in 2006[6][7] and subsequently by Sema4 in 2022,[8] after which it underwent a strategic transformation refocusing on whole exome and genome sequencing in pediatrics and changed its name to GeneDx.[9] Since launching exome testing in 2011,[10] the company has built GeneDx Infinity, a large and diverse rare disease dataset including more than one million clinically sequenced exomes and genomes, more than 2.5 million tests, and more than 8 million phenotypic datapoints.[11][12]

In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter.[13] For full-year 2025, the company reported revenue of approximately $427 million.[14] CEO Katherine Stueland has been recognized on CNBC's Changemakers list in 2025[13] and the TIME100 Health list in 2026.[15] In 2025, GeneDx was named one of Fast Company's Most Innovative Companies, ranked No. 2 in the Biotech category.[16]

History

edit

GeneDx was founded in 2000 by scientists Sherri Bale and John Compton from the National Institutes of Health (NIH).[3][4][5][17][18][19] The company was established to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which limited commercial testing options existed at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD.[3][20]

In 2006, GeneDx was acquired by BioReference Laboratories and continued to operate as a subsidiary.[6][7] In October 2016, Benjamin D. Solomon was appointed as managing director.[21]

In 2021, Katherine Stueland became CEO of GeneDx.[22][23] GeneDx was acquired by Sema4 in 2022, and Stueland was named CEO of the combined company.[8] In 2023, the combined company underwent a strategic transformation, refocusing on whole exome and genome sequencing in pediatrics, and changed its name to GeneDx.[9]

In 2025 GeneDx was named one of Fast Company's Most Innovative Companies, ranked No.2 in the Biotech category.[16] The recognition highlighted the company's work in advancing genomic sequencing and data-driven approaches to improve rare disease diagnosis.

GeneDx settled a patent dispute with Myriad Genetics in February 2015 after GeneDx launched a BRCA mutation breast cancer genetic screening test following the US Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc. that concluded isolated gene sequences were patent ineligible.[24]

Management

edit

Katherine Stueland was appointed CEO of GeneDx in 2021.[22] Under her leadership, the company refocused its operations on exome and genome sequencing for rare disease diagnosis. Stueland has been recognized for her work in genomic medicine, including being named to CNBC's Changemakers list in 2025[13] and to the TIME100 Health list in 2026.[15]

Kevin Feeley was appointed CFO in 2022. Prior to joining GeneDx, Feeley served as CFO of BioReference Laboratories and held senior roles at KPMG LLP.[25]

Bryan Dechairo was appointed COO in 2025.[26]

Products and Services

edit

GeneDx offers genetic testing services with a primary focus on whole genome sequencing (WGS) and whole exome sequencing (WES). WGS provides a comprehensive analysis of an individual's entire genome, while WES focuses on protein-coding regions called exons, which contain a majority of known disease-related genetic variants.[27] The company's tests are used in clinical diagnostics, research, and precision medicine by geneticists, genetic counselors, neonatologists, pediatric specialists, and pediatricians.

GeneDx offers testing for conditions including rare diseases, autism spectrum disorders, epilepsy, neurodevelopmental disorders, cardiomyopathies, and inherited conditions affecting vision, the immune system, muscles, hearing, metabolism, neurology, and mitochondrial diseases. GeneDx also offers rapid sequencing options intended for critically ill pediatric and neonatal patients where timely results may influence acute medical management.[1] GeneDx continues to develop genetic testing technologies and expand access to genomic information for clinical use in pediatric, adult, and newborn populations.

Professional guidelines from organizations such as the American College of Medical Genetics and Genomics (ACMG) and the American Academy of Pediatrics (AAP) support the use of exome or genome sequencing as first-line or early diagnostic tests in selected patient populations.[28][29]

GeneDx's biopharma business focuses on leveraging GeneDx Infinity to provide partners with access to molecularly confirmed genomic data, longitudinal patient information, and curated phenotypic data to support drug discovery, clinical development, real-world evidence generation and other therapeutic development needs.[12][30] By combining large-scale sequencing data with clinical and phenotypic context, the company aims to accelerate rare disease research and improve the efficiency and success rate of biopharmaceutical development programs.

Developments and Milestones

edit

Breakthrough Device Designation

In October 2025, the company's ExomeDx and GenomeDx testing was granted FDA Breakthrough Device designation for use in diagnosing symptomatic patients with life-threatening diseases or genetic disorders.[31]

Acquisition of Fabric Genomics

In April 2025, GeneDx announced the acquisition of Fabric Genomics, an AI-powered genomic interpretation company. The transaction closed in May 2025 for up to $33 million in cash at closing, with total consideration potentially reaching $51 million upon achievement of certain milestones.[32][33]

Financial Performance

In 2024, GeneDx reported revenue of $302.3 million, representing 56% year-over-year growth, and announced its first profitable quarter in October 2024.[13] For full-year 2025, the company reported revenue of approximately $427 million.[14]

Genomic Newborn Screening

GeneDx is a sequencing and interpretation partner in the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, a research initiative examining whether whole genome sequencing can improve health outcomes for newborns. The study is conducted in collaboration with Columbia University, NewYork-Presbyterian, the New York State Department of Health, and Illumina.[34] Results from the study were published in JAMA in October 2024, reporting a 3.7% screen-positive rate among enrolled newborns. 92% of true-positives would not have been detected using standard newborn screening technology.[35] The study has enrolled over 20,000 newborns and expanded its panel to include 446 genes associated with more than 460 actionable conditions.[36][23] The GUARDIAN study was recognized by JAMA as Research of the Year for 2025.[36]

Additionally, GeneDx is a partner in Florida's Sunshine Genetics Program, the first state-supported initiative to integrate genomic sequencing into newborn screening.[37][38]

Research Contributions

edit

GeneDx researchers have contributed to peer-reviewed publications in major scientific and medical journals, generating critical data to expand access to genomic testing. In 2020, GeneDx researchers co-authored a study published in Nature analyzing data from 31,058 exome trios to identify 28 previously undescribed genes associated with developmental disorders, providing diagnoses for approximately 500 families.[39] A 2021 study in JAMA, using data from GeneDx, found that exome sequencing identified pathogenic or likely pathogenic variants in 32.7% of pediatric patients with cerebral palsy, providing evidence to support genetic testing guidelines for the condition.[40]

In 2025, GeneDx collaborated with Seattle Children's and the University of Washington on the SeqFirst research program, which produced two landmark publications. The SeqFirst-Neo study, published in the American Journal of Human Genetics, found that applying broad exclusion criteria for rapid genome sequencing in NICUs increased the odds of a precise genetic diagnosis ninefold compared to conventional care, with 42% of diagnosed infants having been missed under standard protocols.[41] A companion study published in The Journal of Pediatrics demonstrated that implementing rapid genome sequencing as a first-tier test in non-critical pediatric inpatient wards reduced the average time to a precise genetic diagnosis from 289 days to 13 days.[42]

As of 2025, GeneDx has contributed to more than 1,100 peer-reviewed publications and contributes to more than 500 validated gene-disease associations through the GeneMatcher platform.[43]

In 2026, GeneDx researchers published a validation study in Human Genetics describing Multiscore, an AI-powered gene prioritization tool, that combines machine learning with real-world clinical data from the GeneDx database alongside published literature and OMIM, correctly prioritized the causative gene within the top 10 candidates in 83.5% of cases, outperforming existing phenotype-based prioritization tools including Phrank and LIRICAL.[44]

A 2026 real-world health economics analysis (SAVES-Kids), presented at the American College of Medical Genetics (ACMG) annual meeting, found GeneDx's exome and genome sequencing reduced total healthcare costs by up to 61% in the 12 months following testing for children with neurodevelopmental disorders. For children with epilepsy, that represents an average of approximately $80,000 per patient per year.[45]

References

edit
  1. 1 2 "GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options". CNBC. 2025-07-30. Retrieved 2026-04-21.
  2. ↑ Krechevsky, David (2025-07-29). "Stamford-based GeneDx tops $100M in revenue in Q2, posts 4th straight profitable quarter". Hartford Business Journal. Retrieved 2026-04-07.
  3. 1 2 3 "GeneDX Founders Find Market for Diagnostic Tests". The Washington Post. Retrieved 2023-05-27.
  4. 1 2 "Maryland's Incubator Update" (PDF). Maryland State Archives. Retrieved 2023-05-27.
  5. 1 2 "Rebranded GeneDx Bets Future on Whole-Exome, Whole-Genome Sequencing in Pediatric Rare Disease". GenomeWeb. Retrieved 2023-05-27.
  6. 1 2 "N.J. biotech pays $17M in stock, cash for GeneDx". Bizjournals.com.
  7. 1 2 "Bio-Reference Laboratories Announces Agreement to Acquire GeneDx". Genomics Research from Technology Networks. Retrieved 2026-04-21.
  8. 1 2 "Document". www.sec.gov. Retrieved 2026-04-21.
  9. 1 2 Kaufman, Richard; Staff, Patch (2023-01-10). "CT-Based Sema4 Announces Name Change". Stamford, CT Patch. Retrieved 2026-04-23.
  10. ↑ "GeneDx Celebrates 20 Year History as Pioneer In Genetic Sequencing and Testing". News. 2025-07-16. Retrieved 2026-04-07.
  11. ↑ "GeneDx Infinity™ Pioneers a New Era of Genetic Medicine With Its Introduction at the American Academy of Pediatrics National Conference". Genomics Research from Technology Networks. Retrieved 2026-04-07.
  12. 1 2 "Katherine Stueland – CEO, GeneDx". PharmaBoardroom. Retrieved 2026-04-21.
  13. 1 2 3 4 Rosenbaum, Eric (2025-02-24). "Katherine Stueland". CNBC. Retrieved 2026-04-21.
  14. 1 2 "Document". www.sec.gov. Retrieved 2026-04-21.
  15. 1 2 "TIME100 Health 2026". TIME. 2026-03-17. Retrieved 2026-04-21.
  16. 1 2 "The World's 50 Most Innovative Companies of 2025 | Fast Company". Fast Company. Archived from the original on 2026-03-17. Retrieved 2026-04-21.
  17. ↑ "Montgomery College (Pinkney Innovation Complex for Science and Technology Foundation Officers)". Montgomery College. Retrieved 2023-05-27.
  18. ↑ "Preliminary Offering Circular: GeneSystems, Inc". Securities and Exchange Commission Archives. Retrieved 2023-05-27.
  19. ↑ "FORM 10-K/A: Bio-Reference Laboratories, Inc". Securities and Exchange Commission Archives. Retrieved 2023-05-27.
  20. ↑ "Homepage - Maryland State Archives". msa.maryland.gov. Retrieved 2026-04-07.
  21. ↑ "OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx". www.businesswire.com. 2016-09-27. Retrieved 2019-07-18.
  22. 1 2 Taylor, Harriet (2025-10-14). "How a reluctant CEO conquered imposter syndrome to turn a biotech profitable". CNBC. Retrieved 2026-04-21.
  23. 1 2 Finley, Allysia (2025-09-12). "Opinion | The Genetic Answer to Rare Diseases". The Wall Street Journal. Retrieved 2026-04-21.
  24. ↑ "GeneDx, Myriad Settle BRCA Patent Litigation". www.genomeweb.com. 16 February 2015.
  25. ↑ Corp, GeneDx Holdings (2022-08-26). "Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer". GlobeNewswire News Room. Retrieved 2026-04-21.
  26. ↑ "GeneDx Bryan Dechairo". GenomeWeb. 2025-01-03. Retrieved 2026-04-21.
  27. ↑ "What are whole exome sequencing and whole genome sequencing?: MedlinePlus Genetics". medlineplus.gov. Retrieved 2026-04-21.
  28. ↑ Manickam, Kandamurugu; McClain, Monica R.; Demmer, Laurie A.; Biswas, Sawona; Kearney, Hutton M.; Malinowski, Jennifer; Massingham, Lauren J.; Miller, Danny; Yu, Timothy W.; Hisama, Fuki M.; ACMG Board of Directors (November 2021). "Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)". Genetics in Medicine: Official Journal of the American College of Medical Genetics. 23 (11): 2029–2037. doi:10.1038/s41436-021-01242-6. ISSN 1530-0366. PMID 34211152.
  29. ↑ Morgan Ebert (2026-04-21). "AAP updates guidance on genetic testing for developmental delay". Contemporary Pediatrics. Retrieved 2026-04-21.
  30. ↑ "GeneDx Launches Data Visualization Tool to Fuel Drug Development". Global Genes. Retrieved 2026-04-21.
  31. ↑ Morgan Ebert, Managing (2026-04-21). "GeneDx receives FDA Breakthrough Device Designation for whole genome and exome tests". Contemporary Pediatrics. Retrieved 2026-04-21.
  32. ↑ "In Brief This Week: Thermo Fisher Scientific, GeneDx, IDT, Psomagen, Danaher, More". GenomeWeb. 2025-05-09. Retrieved 2026-04-21.
  33. ↑ "GeneDx to Acquire Fabric Genomics in Deal Potentially Worth $51M". GenomeWeb. 2025-04-16. Retrieved 2026-04-21.
  34. ↑ "In Pioneering Study, Gene Technology Outperforms Standard Newborn Screening Tests". Columbia University Irving Medical Center. 2024-10-23. Retrieved 2026-04-21.
  35. ↑ Ziegler, Alban; Koval-Burt, Carrie; Kay, Denise M.; Suchy, Sharon F.; Begtrup, Amber; Langley, Katherine G.; Hernan, Rebecca; Amendola, Laura M.; Boyd, Brenna M.; Bradley, Jennifer; Brandt, Tracy; Cohen, Lilian L.; Coffey, Alison J.; Devaney, Joseph M.; Dygulska, Beata (2025-01-21). "Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions". JAMA. 333 (3): 232–240. doi:10.1001/jama.2024.19662. ISSN 1538-3598. PMC 11503470. PMID 39446378.
  36. 1 2 Abbasi, Jennifer; Anderer, Samantha; Rubin, Rita; Schweitzer, Kate (2026-01-13). "Research of the Year 2025". JAMA. 335 (2): 107–110. doi:10.1001/jama.2025.20503. ISSN 1538-3598. PMID 41385240.
  37. ↑ Albert, Helen (2025-10-14). "GeneDx Announced as Sequencing Partner for Sunshine Genetics Act Pilot". Inside Precision Medicine. Retrieved 2026-04-23.
  38. ↑ Quick, Brad (2026-02-10). "Florida law models what genetic disease testing could be". CNBC. Retrieved 2026-04-23.
  39. ↑ Chundru, V. Kartik; Zhang, Zhancheng; Walter, Klaudia; Lindsay, Sarah J.; Danecek, Petr; Eberhardt, Ruth Y.; Gardner, Eugene J.; Malawsky, Daniel S.; Wigdor, Emilie M.; Torene, Rebecca; Retterer, Kyle; Wright, Caroline F.; Ólafsdóttir, Hildur; Guillen Sacoto, Maria J.; Ayaz, Akif (October 2024). "Federated analysis of autosomal recessive coding variants in 29,745 developmental disorder patients from diverse populations". Nature Genetics. 56 (10): 2046–2053. doi:10.1038/s41588-024-01910-8. ISSN 1546-1718.
  40. ↑ Moreno-De-Luca, Andrés; Millan, Francisca; Pesacreta, Denis R.; Elloumi, Houda Z.; Oetjens, Matthew T.; Teigen, Claire; Wain, Karen E.; Scuffins, Julie; Myers, Scott M.; Torene, Rebecca I.; Gainullin, Vladimir G.; Arvai, Kevin; Kirchner, H. Lester; Ledbetter, David H.; Retterer, Kyle (2021-02-02). "Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy". JAMA. 325 (5): 467–475. doi:10.1001/jama.2020.26148. ISSN 1538-3598. PMC 7856544. PMID 33528536.
  41. ↑ Wenger, Tara L.; Scott, Abbey; Kruidenier, Lukas; Sikes, Megan; Keefe, Alexandra; Buckingham, Kati J.; Marvin, Colby T.; Shively, Kathryn M.; Bacus, Tamara; Sommerland, Olivia M.; Anderson, Kailyn; Gildersleeve, Heidi; Davis, Chayna J.; Love-Nichols, Jamie; MacDuffie, Katherine E. (2025-03-06). "SeqFirst: Building equity access to a precise genetic diagnosis in critically ill newborns". The American Journal of Human Genetics. 112 (3): 508–522. doi:10.1016/j.ajhg.2025.02.003. ISSN 0002-9297.
  42. ↑ Keefe, Alexandra C.; Scott, Abbey A.; Kruidenier, Lukas; Conta, Jessie; Sternen, Darci; Candadai, Sarah Clowes; Stasi, Shannon M.; Parish-Morris, Julia; Sikes, Megan; Adam, Margaret P.; Beck, Anita E.; Hayek, Jennifer C.; Glass, Ian; Bennett, James T.; Mirzaa, Ghayda (2025-11-01). "Implementation of First-Line Rapid Genome Sequencing in Non–Critical Care Pediatric Wards". The Journal of Pediatrics. 286. doi:10.1016/j.jpeds.2025.114699. ISSN 0022-3476. PMID 40562302.
  43. ↑ Torti, Erin; Redlich, Olivia; McGivern, Bobbi; Morrow, Michelle; Mitchell, Dana; Poll, Sarah; Begtrup, Amber; Carere, Deanna Alexis; Crunk, Amy; Facio, Flavia; Frank, Julie; Sacoto, Maria Guillen; Johnson, Britt; Juusola, Jane; Kelly, Kirsten (2026-01-01). "P565: GeneMatcher-facilitated collaborative research ends diagnostic odysseys: From candidate gene cohorts to diagnostic reports*". Genetics in Medicine Open. 2026 ACMG Annual Clinical Genetics Meeting, March 10-14, Baltimore, Maryland, USA. 4 104056. doi:10.1016/j.gimo.2026.104056. ISSN 2949-7744.
  44. ↑ Ustach, Vincent (February 2026). "Multiscore, a gene ranker powered by artificial intelligence and real-world clinical data, shows high sensitivity for the molecular diagnosis of Mendelian disorders in nearly 10,000 exomes and genomes". Human Genetics.
  45. ↑ Genen, Linda (April 3, 2026). "The $80,000 clue hiding in plain sight in U.S. healthcare".
Retrieved from "https://en.wikipedia.org/w/index.php?title=GeneDx&oldid=1355317684"